M. Erol TURAÇLI, Avşin Filiz ÖZDEMİR, Kurnaz Oya TEKELİ

Psödoeksfolyasyonlu hastalarda serum lipid düzeyleri

Amaç: Psödoeksfolyatif (pex) glokomlu olgularda serum lipid seviyelerini kontrol grubu ile karşılaştırmak. Gereç ve yöntem: Çalışmaya 81 pex glokomlu hasta, 26 pex sendromlu hasta ve 67 kontrol olgusu dahil edildi. Tüm olguların serumlarında total kolesterol, HDL- kolesterol, LDL- kolesterol, VLDL- kolesterol ve trigliserid düzeyi ölçüldü. Bulgular: Total kolesterol, HDL- kolesterol, LDL- kolesterol seviyeleri açısından gruplar arasında istatistiksel farklılık saptanmadı ( p>0.05 ). VLDL- kolesterol ve trigliserid düzeyi ise kontrol grubunda pex glokomlu ve pex sendromlu gruba göre belirgin olarak daha yüksekti (sırasıyla; p=0.017, p=0.010). Sonuç: Serum lipid düzeyi ve psödoeksfolyasyon arasında bir ilişki saptanmadı.

Plasma lipid levels in patients with pseudoexfoliation

Aim: To determine plasma lipid levels in patients with pseudoexfoliation (pex) glaucoma. Methods: Eighty-one patients with pex glaucoma, 26 patients with pex syndrome and 67 controls were included into this study group. Plasma total cholesterol, HDL- cholesterol, LDL-cholesterol, VLDL-cholesterol and trigliserid levels were measured. Results: There was no statisticillay significant difference among the groups in terms of total cholesterol, HDL-cholesterol and LDL- cholesterol levels ( p>0.05 ). VLDL-cholesterol and trigliserid levels were significantly higher in controls than pseudoexfoliation glaucoma and syndrome (respectively; p=0.017, p=0.010). Conclusion: There was no relation between plasma lipid levels and pseudoexfoliation.

PDF

___

1. Streeten BW. Aberrant synthesis and aggregation of elastic tissue components in pseudoexfoliation fibrillopathy: a unifying concept. New Trends Ophthalmol 1993; 8:187-196. 2. Schlötzer-Schrehardt U, von der Mark K, Sakai LY, Naumann GOH. Increased extracellular deposition of fibrillin-containing fibrils in pseudoexfoliation syndrome. Invest Ophthalmol Vis Sci 1997; 38:970-984. 3. Ritch R, Schlötzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol 2001; 45: 265-315. 4. Wittchen HU, Glaesmer M, Marz W, et al. Cardiovascular risk factors in primary care: methods and baseline prevalence rates--the DETECT program. Curr Med Res Opin. 2005; 21:619-30. 5. Mitchell P, Wang JJ, Smith W. Association of pseudoexfoliation syndrome with increased vascular risk. Am J Ophthalmol. 1997; 124(5):685-7. 6. Nicholls S, Lundman P. The emerging role of lipoproteins in atherogenesis: beyond LDL cholesterol. Semin Vasc Med. 2004; 4:187-95. 7. Tyagi SC, Kumar S, Katwa L. Differential Regulation of Extracellular Matrix Metalloproteinase and Tissue Inhibitor by Heparin and Cholesterol in Fibroblast Cells. J Mol Cell Cardiol. 1997; 29:391-404. 8. Schlotzer-Schrehardt U, Lommatzsch J, Kuchle M, Konstas AG, Naumann GO. Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/ glaucoma and primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2003; 44:1117-25.